About Menarini Group
Menarini Group is a leading international pharmaceutical and diagnostics company with revenues in excess of US 4.7 billion and over 17,000 employees. Menarini focuses on developing products in areas of unmet therapeutic need, including cardiology, oncology, respiratory medicine, gastroenterology, infectious diseases, diabetes, inflammation and analgesia. Menarini has 18 production sites and 9 R&D centers, and its products are sold in 140 countries around the world. For more information, please visit Menarini.
Stemline Therapeutics, Inc. “Stemline”, a wholly owned finland telegram data subsidiary of Menarini Group, is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics. Stemline launches ORSERDU® elacestrant in the US and EU, an oral endocrine therapy for the treatment of patients with estrogen receptor ER-positive, human epidermal growth factor receptor 2 HER2-negative, ESR1-mutated advanced or metastatic breast cancer whose disease has progressed after at least one line of endocrine therapy. Stemline also launched ELZONRIS® tagraxofusp-erzs in the U. and Europe, an innovative targeted therapy for CD123, for the treatment of patients with blastic plasmacytoid dendritic cell neoplasm BPDCN, an aggressive blood cancer. It is the only approved treatment for BPDCN in the U. and EU to date. Stemline also commercializes NEXPOVIO® selinexor, an XPO1 inhibitor for the treatment of multiple myeloma, in Europe. In addition, Stemline has a broad pipeline of small molecule and biologic clinical products in various stages of development for the treatment of a variety of solid and blood cancers.